Spray-on skin technology saving lives of many in Australia and around the world

The Bali bombing in 2002 caused the shocking deaths of 202 people, including 88 Australians. A further 209 were injured, many with disfiguring burns. But thanks to plastic surgeon Professor Fiona Wood, from the Royal Perth Hospital, a spray-on skin she invented saved many lives. RECELL continues to do so today around the world, thanks […]

AVITA Therapeutics Powers BioScience Managers to Prestigious Australian Investment Council Award

Melbourne, Australia 7 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd has received the 2020 Best Venture Capital Investment Award at the prestigious Australian Investment Council Investing for Growth Awards 2020.   The Best Venture Capital Investment Award recognises BioScience Managers’ patient eight-year investment in AVITA Therapeutics, Inc., a regenerative medicine company that […]

First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction

Link to Full Article Study to enroll a minimum of 65 patients across the United States to evaluate safety and effectiveness of treatment of acute, non-burn skin injuries Valencia, Calif., USA, and Melbourne, Australia, 3, March 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to […]

AVITA Medical Half-Year Financial Report for Fiscal 2020

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 19 February 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that it filed today with the Australian Securities Exchange (ASX) its Appendix 4D – Half-Year […]

AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update

Link to Full Article U.S. RECELL® System product sales of A$4.66M for fiscal second quarter Valencia, Calif., USA, and Melbourne, Australia, 31 January 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the […]

AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo

Link to Full Article Study expected to commence in first half of 2020 Valencia, Calif., USA, and Melbourne, Australia, 30 December 2019 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the U.S. Food and […]

AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa

Link to Full Article AVITA Medical secures option for exclusive licensing of emerging technologies Preclinical research will pair AVITA Medical’s Spray-On Skin™ Cells technology and expertise with the Gates Center’s patent pending combined reprogramming and gene editing methodology Valencia, Calif., USA, Melbourne, Australia, and Aurora, Colo., USA, 25 November 2019 — AVITA Medical (ASX: AVH, […]

AVITA Medical Names David McIntyre as Chief Financial Officer

Link to Full Article • Appointment Enhances Executive Leadership Team as AVITA Medical Broadens Access to Investors and Continues Growth Trajectory • Interim CFO Tim Rooney Remains with Company as Chief Administrative Officer Valencia, Calif., USA, and Melbourne, Australia, 18 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a […]

AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, […]

AVITA Medical Added to S&P/ASX 200 Index

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 8 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the company will be added to the S&P/ASX 200 index, effective upon market open […]